DNLI - Denali Therapeutics Inc
Denali Therapeutics Inc Logo

DNLI - Denali Therapeutics Inc

https://www.denalitherapeutics.com
Hold Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-10 (Snapshot)

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company is headquartered in South San Francisco, California.

52W High
$33.33
52W Low
$10.57
MA Status:
50D: Above 200D: Below
Beta (~1 neutral, <0.9 lower risk)
1.23
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-8.66
EV/Revenue (<3 favorable)
2843.16
P/S (TTM) (<3 favorable)
3643.65
P/B (<3 favorable)
2.20
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
9.83%
Institutions (25–75% balanced)
96.26%
Shares Outstanding
146,212,000
Float
131,926,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
0
Gross Profit (TTM)
-396,059,008
EPS (TTM)
-2.81
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
N/A
ROE (TTM) (>15% strong)
-0.40%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
-1.00
Momentum
Bearish momentum
Value
0.3256
Previous
0.3235
Trend
Rising
Signal Cross
No cross
As of
Sep. 05, 2025